David Scott Jones net worth and biography

David Jones Biography and Net Worth

Chief Commercial Officer of Eyepoint Pharmaceuticals

As Chief Commercial Officer of EyePoint, Scott Jones draws on his significant experience commercializing drugs and devices globally to drive forward the commercialization of innovative ophthalmic products. Prior to joining EyePoint in 2019, Mr. Jones served as Chief Commercial Officer and Vice President, Business Development, at Notal Vision, where he built the organization’s commercial and growth strategy. Mr. Jones’ tenure at Notal Vision also included his role as President, in which he was responsible for developing a business model in the US that would allow for a telemonitoring platform to be covered by Medicare. He previously served as President of QLT Ophthalmics, where he created the strategy and infrastructure for a US commercial operation, and also navigated healthcare policy through roles of varying responsibility at Novartis, including Executive Director, Health Policy, and Executive Director and Head of Market Access and Government Affairs at Novartis Ophthalmics. Mr. Jones began his career with Geigy Pharmaceuticals as a medical representative and subsequently as a hospital sales representative for Ciba-Geigy Pharmaceuticals. He holds a B.S. in Chemistry, an M.A. in Political Science, and a Certificate in Public Administration from the University of Florida.

What is David Scott Jones' net worth?: The estimated net worth of David Scott Jones is at least $634.72 thousand as of February 2nd, 2024. Mr. Jones owns 37,962 shares of Eyepoint Pharmaceuticals stock worth more than $634,725 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Jones may own. Additionally, Mr. Jones receives an annual salary of $672,080.00 as Chief Commercial Officer at Eyepoint Pharmaceuticals. Learn More about David Scott Jones' net worth.
How old is David Scott Jones?: Mr. Jones is currently 56 years old. There are 4 older executives and no younger executives at Eyepoint Pharmaceuticals. The oldest executive at Eyepoint Pharmaceuticals is Dr. John B. Landis M.S., Ph.D., Interim Head of R&D and Director, who is 71 years old. Learn More on David Scott Jones' age.
What is David Scott Jones' salary?: As the Chief Commercial Officer of Eyepoint Pharmaceuticals, Inc., Mr. Jones earns $672,080.00 per year. There are 3 executives that earn more than Mr. Jones. The highest earning executive at Eyepoint Pharmaceuticals is Dr. Jay S. Duker M.D., President, CEO & Director, who commands a salary of $848,500.00 per year. Learn More on David Scott Jones' salary.
How do I contact David Scott Jones?: The corporate mailing address for Mr. Jones and other Eyepoint Pharmaceuticals executives is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. Eyepoint Pharmaceuticals can also be reached via phone at (617) 926-5000 and via email at [email protected]. Learn More on David Scott Jones' contact information.
Has David Scott Jones been buying or selling shares of Eyepoint Pharmaceuticals?: David Scott Jones has not been actively trading shares of Eyepoint Pharmaceuticals in the last ninety days. Most recently, David Scott Jones sold 209 shares of the business's stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $28.49, for a transaction totalling $5,954.41. Following the completion of the sale, the senior vice president now directly owns 37,962 shares of the company's stock, valued at $1,081,537.38. Learn More on David Scott Jones' trading history.
Who are Eyepoint Pharmaceuticals' active insiders?: Eyepoint Pharmaceuticals' insider roster includes Wendy Dicicco (Director), and David Jones (Chief Commercial Officer). Learn More on Eyepoint Pharmaceuticals' active insiders.

David Scott Jones Insider Trading History at Eyepoint Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/2/2024	Sell	209	$28.49	$5,954.41	37,962
1/25/2024	Sell	600	$25.00	$15,000.00	37,962
1/23/2024	Sell	900	$25.00	$22,500.00	37,962

David Scott Jones Buying and Selling Activity at Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals Company Overview

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $16.72

$14.40

$17.00

50 Day Range

MA: $13.00

$11.02

$16.72

2 Week Range

Now: $16.72

$3.91

$17.00

Volume

2,029,677 shs

Average Volume

1,004,794 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

David Jones Biography and Net Worth

What is David Scott Jones' net worth?

How old is David Scott Jones?

What is David Scott Jones' salary?

How do I contact David Scott Jones?

Has David Scott Jones been buying or selling shares of Eyepoint Pharmaceuticals?

Who are Eyepoint Pharmaceuticals' active insiders?